Brooks Laboratories AGM resolutions pass with 99.99% shareholder support

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Brooks Laboratories published final e-voting results for its 24th AGM held on September 3, 2026
  • All six ordinary resolutions passed with support exceeding 99.99% from participating shareholders
  • Total votes polled stood at 18,555,905, representing full participation from promoter and public non-institutional holders
  • Key approvals included FY26 financials, director reappointment, and executive remuneration
powered bylight_fuzz_icon
49982112

*this image is generated using AI for illustrative purposes only.

Brooks Laboratories has released the final e-voting results for its 24th Annual General Meeting (AGM), confirming that all six ordinary resolutions were approved by shareholders. The meeting, held on September 3, 2026, via video conference, saw near-unanimous support for the company’s financial statements and management appointments.

The scrutinizer report, issued by G.S. Sarin of Sharma Sarin & Associates on September 4, 2026, details the voting breakdown. A total of 18,555,905 votes were polled across all resolutions, representing 100% of the outstanding shares held by promoters and public non-institutional investors who participated.

Voting Results Breakdown

The voting process was conducted through remote e-voting and e-voting during the AGM. The promoter group held 15,500,292 shares, while public non-institutional shareholders held 3,055,613 shares. No institutional public shareholders voted.

Resolution Description Votes In Favour Votes Against % Support
1 Adoption of FY26 financial statements 18,555,826 79 99.9996%
2 Reappointment of Mr. Jitendra Pratap Singh 18,555,771 134 99.9993%
3 Ratification of cost auditor remuneration 18,555,826 79 99.9996%
4 Approval of related party transactions 18,555,826 79 99.9996%
5 Remuneration for Mr. Atul Ranchal 10,792,753 134 99.9988%
6 Remuneration for Mr. Rajesh Mahajan 10,818,497 134 99.9988%

Key Resolutions Passed

Shareholders approved the adoption of the annual audited standalone and consolidated financial statements for FY26. The reappointment of Mr. Jitendra Pratap Singh as a director, replacing those retiring by rotation, was also ratified.

Additionally, the meeting approved the remuneration for Mr. Atul Ranchal, President – Strategy, and Mr. Rajesh Mahajan, President – Trading, under Section 188(1)(f) of the Companies Act, 2013. Related party transactions and cost auditor remuneration were similarly approved.

Scrutinizer Report Details

The remote e-voting period commenced on August 31, 2026, at 9:00 am and concluded on September 2, 2026, at 5:00 pm. The votes were unblocked on September 3, 2026, in the presence of two independent witnesses. No invalid votes were recorded for Resolutions 1, 2, 3, and 4. For Resolutions 5 and 6, which involved related party interests, some promoter votes were marked invalid due to abstention requirements, though the resolutions still passed with overwhelming support from eligible voters.

Historical Stock Returns for Brooks Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-1.79%-10.16%-20.90%+47.67%-59.18%-58.40%

How might the near-unanimous shareholder approval of FY26 financial statements influence Brooks Laboratories' credit rating or future borrowing costs?

What strategic initiatives are Mr. Atul Ranchal and Mr. Rajesh Mahajan expected to prioritize following the ratification of their remuneration packages?

Could the complete absence of institutional public shareholders in the voting process signal a shift in investor sentiment or liquidity concerns for Brooks Laboratories?

Brooks Laboratories amends AGM resolution for ₹48.15 crore BSL guarantee

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Brooks Laboratories issued an addendum on August 22, 2026, for its September 3 AGM
  • Resolution 4 amended to ratify ₹48.15 crore guarantee for joint venture BSL
  • Proposed FY27 related-party transaction limits total ₹35 crore plus guarantee
  • Aggregate exposure represents 96.99% of prior year consolidated turnover
powered bylight_fuzz_icon
47661444

*this image is generated using AI for illustrative purposes only.

Brooks Laboratories Limited issued an addendum on August 22, 2026, to the notice of its 24th Annual General Meeting (AGM), scheduled for September 3, 2026. The update amends Resolution No. 4 to align with corporate guarantee arrangements involving its jointly controlled entity, Brooks Steriscience Limited (BSL). The company published the addendum in Financial Express and Jansatta on August 22, 2026.

The original AGM notice, dated July 31, 2026, and dispatched on August 12, 2026, remains valid except for the modifications detailed in the addendum. Shareholders must read the addendum collectively with the initial notice and the Annual Report for FY25-26.

Related Party Transaction Details

The amendment seeks shareholder approval to ratify a corporate guarantee of ₹48.15 crore provided in favor of BSL during March 2026. This guarantee was approved by the Audit Committee in its meeting held on February 6, 2026. The company proposes an overall corporate guarantee limit of up to ₹48.15 crore for BSL. Any further guarantees will require enhancement of this limit and applicable approvals.

In addition to the guarantee, the company proposes to continue operational transactions with BSL during FY26-27:

  • Purchase of goods and commissions: up to ₹15 crore
  • Sale of goods and commissions: up to ₹15 crore
  • Job work services and shared services: up to ₹5 crore

The aggregate value of these transactions, including the corporate guarantee limit, represents approximately 96.99% of the company’s annual consolidated turnover for the immediately preceding financial year. Atul Ranchal is identified as a related party director interested in these transactions.

Other AGM Resolutions

The AGM agenda includes several other key resolutions:

  • Cost Auditor Ratification: Ratification of remuneration payable to M/s. Balwinder & Associates for FY26-27 cost audit, amounting to ₹60,000 plus taxes.
  • Director Reappointment: Reappointment of Mr. Jitendrapratap Rambahadur Singh, who retires by rotation.
  • Executive Remuneration: Approval of remuneration for Mr. Atul Ranchal, President – Strategy, at a maximum of ₹15 lakh per month, effective September 1, 2026. Additionally, remuneration for Mr. Rajesh Mahajan, President – Trading, at a maximum of ₹8 lakh per month, effective July 17, 2026.

Key Dates and Logistics

The Register of Members will remain closed from August 27, 2026, through September 3, 2026. Remote e-voting opens on August 31, 2026, at 9:00 am and closes on September 2, 2026, at 5:00 pm. The AGM will be conducted exclusively via Video Conferencing or Other Audio-Visual Means (VC/OAVM), starting at 9:00 am IST.

Event Date/Time Mode
AGM Date September 3, 2026 VC/OAVM
Start Time 9:00 am IST Virtual
Book Closure Start August 27, 2026 N/A
Book Closure End September 3, 2026 N/A
E-Voting Cut-Off August 27, 2026 N/A
Remote E-Voting Start August 31, 2026, 9:00 am IST Online
Remote E-Voting End September 2, 2026, 5:00 pm IST Online

Shareholders are advised to ensure their email addresses are registered with their Depository Participants or the Registrar and Share Transfer Agent, MUFG Intime India Private Limited, to receive communications electronically. Attendance via VC/OAVM counts toward the quorum requirement under Section 103 of the Companies Act, 2013.

Historical Stock Returns for Brooks Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-1.79%-10.16%-20.90%+47.67%-59.18%-58.40%

How might the high concentration of related-party transactions, representing nearly 97% of turnover, impact Brooks Laboratories' operational independence and risk profile in FY26-27?

What are the specific strategic growth drivers for Brooks Steriscience Limited that justify the ₹48.15 crore corporate guarantee and continued financial support from the parent company?

Will the approved remuneration increases for President Atul Ranchal and President Rajesh Mahajan correlate with specific performance targets or expansion goals for the Strategy and Trading divisions?

More News on Brooks Laboratories

1 Year Returns:-59.18%